Zhen Fan, M.D.
Department of Experimental Therapeutics, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Professor, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Full Member, Graduate Faculty, The Graduate School of Biomedical Sciences (GSBS) (Joint appointment), The University of Texas Health Science Center at Houston, Houston, TX
Dual/Joint/Adjunct Appointment
Professor, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX
Full Member, Graduate Faculty, The Graduate School of Biomedical Sciences (GSBS), The University of Texas Health Science Center at Houston, Houston, TX
Research Interests
My laboratory has a track record in investigating the mechanism of action by which trastuzumab (a HER2-targeting antibody) and cetuximab (an EGFR-targeting antibody), 2 FDA-approved therapeutic antibodies, inhibit cancer metabolism (i.e., Warburg effect), tumor angiogenesis, cancer cell stemness, and cancer cell interaction with tumor stroma in the treatment of metastatic breast cancer, colorectal cancer, or head and neck cancer. Through our published work, we also made significant contributions toward our understanding on how aberrations in cancer cell signaling molecules (e.g. Akt, MAPK, MEK, mTOR, PI3K, PTEN, AMPK, Brk, LKB1, HIF-1α, STATs) and signal pathways downstream to HER2 and EGFR render cancer cell resistance to the therapeutic antibodies.
Our current research focuses on 2 directions leveraging existing resources in the laboratory and our expertise in cancer biology, tumor immunology, and antibody engineering & therapies. One direction is to improve antitumor activity of therapeutic antibodies by developing novel bispecific antibody (BsAbs). We design novel platforms of BsAbs for gaining of new mechanism of action, through which BsAbs will exhibit new therapeutic activities that do not exist in simple mixture of 2 parental antibodies. We are currently developing several BsAbs and testing their therapeutic activities in syngeneic mouse tumor models and in PDXs hosted in humanized mice. Our goal is to develop second-generation antibody-based drugs that have multiple therapeutic activities and thus are expected to be more effective than first-generation antibody drugs currently approved to treat cancer patients, such as trastuzumab and cetuximab, especially for treatment of cancer metastasis. Another direction is to redirect preexisting immunity acquired through vaccination or infection of infectious viruses for treating cancer metastasis. Our strategy is to develop an antibody targeting-based therapeutic approach to trick host immune system to perceive cancer cells as infectious virus-infected cells and thereby launch immune responses to attack the cancer cells using powerful preexisting immunity acquired via vaccination or infection of an infectious virus. We have successfully validated this novel strategy in preclinical mouse tumor models.
Education & Training
Degree-Granting Education
| 1988 | Shanghai Medical University, School of Graduate Studies (now Fudan University Graduate School), Shanghai, CN, M.S. in Histology/Embryology |
| 1985 | Shanghai Medical University (SMU), School of Medicine (now Fudan University Shanghai Medical College), Shanghai, CN, MD |
Postgraduate Training
| 1991-1994 | Research Fellowship, Postdoctoral fellow in Program of Molecular Pharmacology and Therapeutics, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, New York |
| 1988-1991 | Clinical Residency, Zhongshan Hospital (SMU Hospital), Shanghai |
| 1984-1985 | Clinical Internship, Huashan Hospital (SMU Hospital), Shanghai |
Experience & Service
Academic Appointments
Associate Professor, Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX, 2002 - 2011
Assistant Professor (tenure track), Department of Clinical Investigations, The University of Texas M D Anderson Cancer Center, Houston, TX, 1996 - 2002
Assistant Laboratory Member and Assistant Molecular Biologist (non-tenure track faculty appointment), Department of Medicine, Memorial Hospital, Memorial Sloan-Kettering Cancer Center, New York, NY, 1996 - 1996
Research Associate, Department of Program of Molecular Pharmacology and Therapeutics, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, NY, 1994 - 1995
Postdoctoral Research Fellow, Department of Program of Molecular Pharmacology and Therapeutics, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, NY, 1991 - 1994
Resident Physician, Zhongshan Hospital of Shanghai Medical University, Shanghai, 1988 - 1991
Other Appointments/Responsibilities
Committee Chair, Experimental Therapeutics Department Seminar Series, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - Present
Committee Member, Experimental Therapeutics Department Mentorship Committee, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - Present
Committee Member, Experimental Therapeutics Department Seminar Series, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - 2013
Institutional Committee Activities
Member (Immunology Program), GSBS Academic Standard Committee, 2021 - Present
Member, GSBS Membership Committee, 2018 - 2020
Member (Therapeutics and Pharmacology Program), GSBS Academic Standard Committee, 2016 - 2018
Member, Institutional Technology Review Committee (TRC), 2012 - 2012
Member, Organizing Committee, Annual Institutional Research Symposium 2011, 2011 - 2011
Member, Institutional Animal Care and Use Committee (IACUC), 2006 - 2009
Member, Institutional Research Grants Program (IRG Basic Science Study Section), 2003 - 2006
Member, Institutional Biosafety Committee (IBC), 1999 - 2002
Honors & Awards
| 2010 | "Wall of Science" for scientific achievements published in high impact Journal, The University of Texas MD Anderson Cancer Center |
| 2010 | Potu N. Rao Award for Excellence in Basic Science, Division of Cancer Medicine Faculty Recognition & Award Program, The University of Texas MD Anderson Cancer Center |
| 1999 | Awardee, Breast Cancer Research Foundation, New York, NY |
| 1999 | Physician Referral Service Executive Council Award, The University of Texas MD Anderson Cancer Center |
| 1999 | Ovarian Cancer Research Program Development Award, The University of Texas MD Anderson Cancer Center |
| 1996 | Project Completion Certificate, State Commission of Science and Technology of China |
| 1996 | First Place Award for Achievements in Science and Technology, City Commission of Science and Technology of Shanghai, China |
| 1990 | Third Place Award for Achievements in Science and Technology, City Commission of Science and Technology of Shanghai, China |
| 1985 | Honor exemption from the nationwide admission examination to the Graduate School of Shanghai Medical University, Shanghai, China |
| 1980 | Honor Student, Shanghai First Medical College, Shanghai, China |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Chaganty BKR, Qiu S, Lu Y, Lopez-Berestein G, Ozpolat B, Fan Z. Redirecting host preexisting influenza A virus immunity for cancer immunotherapy. Cancer Immunol Immunother 71(7):1611-1623, 2022. e-Pub 2022. PMID: 34731283.
- Luo Y, Li W, Ling Z, Hu Q, Fan Z, Cheng B, Tao X. ASCT2 overexpression is associated with poor survival of OSCC patients and ASCT2 knockdown inhibited growth of glutamine-addicted OSCC cells. Cancer Med 9(10):3489-3499, 2020. e-Pub 2020. PMID: 32162845.
- Lu H, Lu Y, Xie Y, Qiu S, Li X, Fan Z. Rational combination with PDK1 inhibition overcomes cetuximab resistance in head and neck squamous cell carcinoma. JCI Insight 4(19), 2019. e-Pub 2019. PMID: 31578313.
- Chaganty BKR, Qiu S, Gest A, Lu Y, Ivan C, Calin GA, Weiner LM, Fan Z. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion. Cancer Lett 430:47-56, 2018. e-Pub 2018. PMID: 29746929.
- Meng S, Wang G, Lu Y, Fan Z. Functional cooperation between HIF-1α and c-Jun in mediating primary and acquired resistance to gefitinib in NSCLC cells with activating mutation of EGFR. Lung Cancer 121:82-90, 2018. e-Pub 2018. PMID: 29858032.
- Tao X, Lu Y, Qiu S, Wang Y, Qin J, Fan Z. AP1G1 is involved in cetuximab-mediated downregulation of ASCT2-EGFR complex and sensitization of human head and neck squamous cell carcinoma cells to ROS-induced apoptosis. Cancer Lett 408:33-42, 2017. e-Pub 2017. PMID: 28823958.
- Luo J, Hong Y, Lu Y, Qiu S, Chaganty BK, Zhang L, Wang X, Li Q, Fan Z. Acetyl-CoA carboxylase rewires cancer metabolism to allow cancer cells to survive inhibition of the Warburg effect by cetuximab. Cancer Lett 384:39-49, 2017. e-Pub 2017. PMID: 27693630.
- Lu H, Li X, Lu Y, Qiu S, Fan Z. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis. Cancer Lett 381(1):23-30, 2016. e-Pub 2016. PMID: 27450723.
- Lu Y, Shi C, Qiu S, Fan Z. Identification and validation of COX-2 as a co-target for overcoming cetuximab resistance in colorectal cancer cells. Oncotarget 7(40):64766-64777, 2016. e-Pub 2016. PMID: 27074568.
- Ai Z, Lu Y, Qiu S, Fan Z. Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism. Cancer Lett 373(1):36-44, 2016. e-Pub 2016. PMID: 26801746.
- Chaganty BK, Lu Y, Qiu S, Somanchi SS, Lee DA, Fan Z. Trastuzumab upregulates expression of HLA-ABC and T cell costimulatory molecules through engagement of natural killer cells and stimulation of IFNγ secretion. Oncoimmunology 5(4):e1100790, 2016. e-Pub 2016. PMID: 27141382.
- Khelwatty SA, Essapen S, Seddon AM, Fan Z, Modjtahedi H. Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers. Br J Cancer 113(7):1010-9, 2015. e-Pub 2015. PMID: 26372697.
- Li X, Lu Y, Lu H, Luo J, Hong Y, Fan Z. AMPK-mediated energy homeostasis and associated metabolic effects on cancer cell response and resistance to cetuximab. Oncotarget 6(13):11507-18, 2015. e-Pub 2015. PMID: 25871473.
- Liang K, Qiu S, Lu Y, Fan Z. Autocrine/paracrine erythropoietin regulates migration and invasion potential and the stemness of human breast cancer cells. Cancer Biol Ther 15(1):89-98, 2014. e-Pub 2014. PMID: 24100272.
- Lu H, Li X, Luo Z, Liu J, Fan Z. Cetuximab reverses the Warburg effect by inhibiting HIF-1-regulated LDH-A. Mol Cancer Ther 12(10):2187-99, 2013. e-Pub 2013. PMID: 23920275.
- Ai M, Qiu S, Lu Y, Fan Z. HER2 regulates Brk/PTK6 stability via upregulating calpastatin, an inhibitor of calpain. Cell Signal 25(9):1754-61, 2013. e-Pub 2013. PMID: 23707532.
- Xu J, Lu Y, Qiu S, Chen ZN, Fan Z. A novel role of EMMPRIN/CD147 in transformation of quiescent fibroblasts to cancer-associated fibroblasts by breast cancer cells. Cancer Lett 335(2):380-6, 2013. e-Pub 2013. PMID: 23474495.
- Ai M, Liang K, Lu Y, Qiu S, Fan Z. Brk/PTK6 cooperates with HER2 and Src in regulating breast cancer cell survival and epithelial-to-mesenchymal transition. Cancer Biol Ther 14(3):237-45, 2013. e-Pub 2013. PMID: 23291984.
- Li X, Lu Y, Liang K, Hsu JM, Albarracin C, Mills GB, Hung MC, Fan Z. Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR. Oncogene 31(40):4372-83, 2012. e-Pub 2012. PMID: 22231447.
- Lu H, Liang K, Lu Y, Fan Z. The anti-EGFR antibody cetuximab sensitizes human head and neck squamous cell carcinoma cells to radiation in part through inhibiting radiation-induced upregulation of HIF-1α. Cancer Lett 322(1):78-85, 2012. e-Pub 2012. PMID: 22348829.
- Bristol ML, Di X, Beckman MJ, Wilson EN, Henderson SC, Maiti A, Fan Z, Gewirtz DA. Dual functions of autophagy in the response of breast tumor cells to radiation: Cytoprotective autophagy with radiation alone and cytotoxic autophagy in radiosensitization by vitamin D3. Autophagy 8(5). e-Pub 2012. PMID: 22498493.
- Luwor RB, Lu Y, Li X, Liang K, Fan Z. Constitutively active Harvey Ras confers resistance to epidermal growth factor receptor-targeted therapy with cetuximab and gefitinib. Cancer Lett 306(1):85-91, 2011. e-Pub 2011. PMID: 21411223.
- Guo W, Chen D, Fan Z, Epstein HF. Differential turnover of myosin chaperone UNC-45A isoforms increases in metastatic human breast cancer. J. Mol biol 412(3):365-78, 2011. e-Pub 2011. PMID: 21802425.
- Zhang G, Brewster A, Guan B, Fan Z, Brown PH, Xu XC. Tumor-suppressor activity of RRIG1 in breast cancer. BMC Cancer 11(32), 2011. e-Pub 2011. PMID: 21266059.
- Wu Y, Li X, Zhu JX, Xie W, Le W, Fan Z, Jankovic J, Pan T. Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease. Neurosignals 19(3):163-74, 2011. e-Pub 2011. PMID: 21778691.
- Lu Y, Li X, Lu H, Fan Z. 1, 9-Pyrazoloanthrones downregulate HIF-1α and sensitize cancer cells to cetuximab-mediated anti-EGFR therapy. PLoS One 5(12):e15823, 2010. e-Pub 2010. PMID: 21209911.
- Li X, Lu Y, Pan T, Fan Z. Roles of autophagy in cetuximab-mediated cancer therapy against EGFR. Autophagy 6(8):1066-1077, 2010. e-Pub 2010. PMID: 20864811.
- Liang K, Esteva FJ, Albarracin C, Stemke-Hale K, Lu Y, Bianchini G, Yang CY, Li Y, Li X, Chen CT, Mills GB, Hortobagyi GN, Mendelsohn J, Hung MC, Fan Z. Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell 18(8):401-2, 2010. e-Pub 2010. PMID: 21075308.
- Chen M, Gu J, Delclos GL, Killary AM, Fan Z, Hildebrandt MA, Chamberlain RM, Grossman HB, Dinney CP, Wu X. Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients. Carcinogenesis 31(8):1387-1391, 2010. e-Pub 2010. PMID: 20530239.
- Li X, Fan Z. The EGFR antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1α and Bcl-2 and activating the beclin-1/hVps34 complex. Cancer Res 70(14):5942–52, 2010. e-Pub 2010. PMID: 20634405.
- Cardó-Vila M, Giordano RJ, Sidman RL, Bronk LF, Fan Z, Mendelsohn J, Arap W, Pasqualini R. From combinatorial peptide selection to drug prototype (II): Targeting the epidermal growth factor receptor pathway. Proc Natl Acad Sci U S A 107(11):5118–5123, 2010. e-Pub 2010. PMID: 20190183.
- Chen M, Cassidy A, Gu J, Delclos GL, Fan Z, Yang H, Hildebrandt MA, Lin J, Ye Y, Chamberlain RM, Dinney CP, Wu X. Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk. Carcinogenesis 30(12):2047-2052, 2009. e-Pub 2009. PMID: 19875696.
- Cunningham MP, Thomas H, Marks C, Green M, Fan Z, Modjtahedi H. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells. Int J Oncol 33(5):1107-13, 2008. e-Pub 2008. PMID: 18949375.
- Li X, Lu Y, Liang K, Pan T, Mendelsohn J, Fan Z. Requirement of hypoxia-inducible factor-1 alpha downregulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab. Mol Cancer Ther 7(5):1207-1217, 2008. e-Pub 2008. PMID: 18483308.
- Lu Y, Liang K, Li X, Fan Z. Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1 alpha. Mol Cancer 6(63):63 (1-13), 2007. e-Pub 2007. PMID: 17931419.
- Lu Y, Li X, Liang K, Luwor R, Siddik ZH, Mills GB, Mendelsohn J, Fan Z. Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. Cancer Res 67:8240-8247, 2007. e-Pub 2007. PMID: 17804738.
- Adams KE, Ke S, Kwon S, Liang F, Fan Z, Lu Y, Hirschi K, Mawad ME, Barry MA, Sevick-Muraca EM. Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer. J Biomed Opt 12(2):1-9, 2007. e-Pub 2007. PMID: 17477732.
- Cunningham MP, Thomas H, Fan Z, Modjtahedi H. Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib. Cancer Res 66:7708-7715, 2006. e-Pub 2006. PMID: 16885373.
- Li X, Luwor RB, Lu Y, Liang K, Fan Z. Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTEN-deficient cancer cells. Oncogene 25:525-535, 2006. e-Pub 2006. PMID: 16170346.
- Liang K, Lu Y, Li X, Zeng X, Glazer IR, Mills GB, Fan Z. Differential roles of phosphoinositide-dependent protein kinase-1 and Akt1 expression and phosphorylation in breast cancer cell resistance to paclitaxel, doxorubicin, and gemcitabine. Mol Pharmacol 70:1045-1052, 2006. e-Pub 2006. PMID: 16782806.
- Li X, Lu Y, Jin W, Liang K, Mills GB, Fan Z. Autophosphorylation of Akt at threonine-72 and serine-246: A potential mechanism of regulation of Akt kinase activity. J Biol Chem 281:13837-13843, 2006. e-Pub 2006. PMID: 16549426.
- Zhang L, Zhu H, Teraishi F, Davis JJ, Guo W, Fan Z, Fang B. Accelerated degradation of caspase-8 protein correlates with TRAIL resistance in a DLD1 human colon cancer cell line. Neoplasia 7:594-602, 2005. e-Pub 2005. PMID: 16036110.
- Luwor RB, Lu Y, Li X, Mendelsohn J, Fan Z. The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. Oncogene 24:4433-4441, 2005. e-Pub 2005. PMID: 15806152.
- Li X, Lu Y, Liang K, Liu B, Fan Z. Differential responses to doxorubicin-induced phosphorylation and activation of Akt in human breast cancer cells. Breast Cancer Res 7:R589-597, 2005. e-Pub 2005. PMID: 16168102.
- Nakata E, Hunter N, Mason K, Fan Z, Ang KK, Milas L. C225 antiepidermal growth factor receptor antibody enhances the efficacy of docetaxel chemoradiotherapy. Int J Radiat Oncol Biol Phys 59:1163-1173, 2004. e-Pub 2004. PMID: 15234052.
- Liang K, Lu Y, Jin W, Ang KK, Milas L, Fan Z. Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther 2:1113-20, 2003. e-Pub 2003. PMID: 14617784.
- Liang K, Ang KK, Milas L, Hunter N, Fan Z. The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 57:246-254, 2003. e-Pub 2003. PMID: 12909240.
- Jin W, Wu L, Liang K, Liu B, Lu Y, Fan Z. Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells. Br J Cancer 89:185-191, 2003. e-Pub 2003. PMID: 12838322.
- Vega J, Ke S, Fan Z, Wallace S, Charsangavej C, Li C. Targeting doxorubicin to epidermal growth factor receptors by site-specific conjugation of C225 to poly(L-glutamic acid) through a polyethylene glycol spacer. Pharm Res 20:826-832, 2003. e-Pub 2003. PMID: 12751641.
- Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, Schmidt M, Mills GB, Mendelsohn J, Fan Z. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22:3205-3212, 2003. e-Pub 2003. PMID: 12761490.
- Liang K, Jin W, Knuefermann C, Schmidt M, Mills GB, Ang KK, Milas L, Fan Z. Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy. Mol Cancer Ther 2:353-360, 2003. e-Pub 2003. PMID: 12700279.
- Sclabas GM, Fujioka S, Schmidt C, Fan Z, Evans DB, Chiao PJ. Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-kappaB signaling pathway with the anti-epidermal growth factor antibody IMC-C225. J Gastrointest Surg 7:37-43, 2003. e-Pub 2003. PMID: 12559183.
- Sweeney P, Karashima T, Kim SJ, Kedar D, Mian B, Huang S, Baker C, Fan Z, Hicklin DJ, Pettaway CA, Dinney CP. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Clin Cancer Res 8:2714-2724, 2002. e-Pub 2002. PMID: 12171905.
- Liu B, Peng D, Lu Y, Jin W, Fan Z. A novel single amino acid deletion caspase-8 mutant in cancer cells that lost proapoptotic activity. J Biol Chem 277:30159-30164, 2002. e-Pub 2002. PMID: 12055196.
- Karashima T, Sweeney P, Slaton JW, Kim SJ, Kedar D, Izawa JI, Fan Z, Pettaway C, Hicklin DJ, Shuin T, Dinney CP. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin Cancer Res 8:1253-1264, 2002. e-Pub 2002. PMID: 12006546.
- Patrick CW, Zheng B, Schmidt M, Herman PS, Chauvin BP, Fan Z, Stark B, Evans GR. Dermal fibroblasts genetically engineered to release nerve growth factor. Ann Plast Surg 47:660-665, 2001. e-Pub 2001. PMID: 11756838.
- Schmidt M, Lu Y, Parant JM, Lozano G, Bacher G, Beckers T, Fan Z. Differential roles of p21(Waf1) and p27(Kip1) in modulating chemosensitivity and their possible application in drug discovery studies. Mol Pharmacol 60(5):900-6, 2001. e-Pub 2001. PMID: 11641417.
- Nasu S, Ang KK, Fan Z, Milas L. C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int J Radiat Oncol Biol Phys 51:474-477, 2001. e-Pub 2001. PMID: 11567823.
- Schmidt M, Fan Z. Protection against chemotherapy-induced cytotoxicity by cyclin-dependent kinase inhibitors (CKI) in CKI-responsive cells compared with CKI-unresponsive cells. Oncogene 20:6164-6171, 2001. e-Pub 2001. PMID: 11593424.
- Liu B, Fang M, Lu Y, Lu Y, Mills GB, Fan Z. Involvement of JNK-mediated pathway in EGF-mediated protection against paclitaxel-induced apoptosis in SiHa human cervical cancer cells. Br J Cancer 85:303-311, 2001. e-Pub 2001. PMID: 11461094.
- Wen X, Wu QP, Lu Y, Fan Z, Charnsangavej C, Wallace S, Chow D, Li C. Poly(ethylene glycol)-conjugated anti-EGF receptor antibody C225 with radiometal chelator attached to the termini of polymer chains. Bioconjug Chem 12:545-553, 2001. e-Pub 2001. PMID: 11459459.
- Liu B, Fan Z. The monoclonal antibody 225 activates caspase-8 and induces apoptosis through a tumor necrosis factor receptor family-independent pathway. Oncogene 20:3726-3734, 2001. e-Pub 2001. PMID: 11439335.
- Liu B, Fang M, Lu Y, Mendelsohn J, Fan Z. Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody. Oncogene 20:1913-1922, 2001. e-Pub 2001. PMID: 11313939.
- Wang L, Liu B, Schmidt M, Lu Y, Wels W, Fan Z. Antitumor effect of an HER2-specific antibody-toxin fusion protein on human prostate cancer cells. Prostate 47:21-28, 2001. e-Pub 2001. PMID: 11304726.
- Schmidt M, McWatters A, White RA, Groner B, Wels W, Fan Z, Bast RC, Jr. Synergistic interaction between an anti-p185HER-2 pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA] and ionizing radiation for inhibiting growth of ovarian cancer cells that overexpress HER-2. Gynecol Oncol 80:145-155, 2001. e-Pub 2001. PMID: 11161852.
- Liu B, Fang M, Schmidt M, Lu Y, Mendelsohn J, Fan Z. Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity. Br J Cancer 82:1991-1999, 2000. e-Pub 2000. PMID: 10864208.
- Schmidt M, Lu Y, Liu B, Fang M, Mendelsohn J, Fan Z. Differential modulation of paclitaxel-mediated apoptosis by p21Waf1 and p27Kip1. Oncogene 19:2423-2429, 2000. e-Pub 2000. PMID: 10828884.
- Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K, Mendelsohn J, Fan Z. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6:701-708, 2000. e-Pub 2000. PMID: 10690556.
- Fang M, Liu B, Schmidt M, Lu Y, Mendelsohn J, Fan Z. Involvement of p21Waf1 in mediating inhibition of paclitaxel-induced apoptosis by epidermal growth factor in MDA-MB-468 human breast cancer cells. Anticancer Res 20:103-111, 2000. e-Pub 2000. PMID: 10769641.
- Ye D, Mendelsohn J, Fan Z. Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells. Clin Cancer Res 5:2171-2177, 1999. e-Pub 1999. PMID: 10473102.
- Chou JL, Fan Z, DeBlasio T, Koff A, Rosen N, Mendelsohn J. Constitutive overexpression of cyclin D1 in human breast epithelial cells does not prevent G1 arrest induced by deprivation of epidermal growth factor. Breast Cancer Res Treat 55:267-83, 1999. e-Pub 1999. PMID: 10517171.
- Ciardiello F, Bianco R, Damiano V, De Lorenzo S, Pepe S, De Placido S, Fan Z, Mendelsohn J, Bianco AR, Tortora G. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 5:909-916, 1999. e-Pub 1999. PMID: 10213228.
- Ye D, Mendelsohn J, Fan Z. Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene 18:731-738, 1999. e-Pub 1999. PMID: 9989823.
- Bromberg JF, Fan Z, Brown C, Mendelsohn J, Darnell JE, Jr. Epidermal growth factor-induced growth inhibition requires Stat1 activation. Cell Growth Differ 9:505-512, 1998. e-Pub 1998. PMID: 9690618.
- Fan Z, Shang BY, Lu Y, Chou JL, Mendelsohn J. Reciprocal changes in p27(Kip1) and p21(Cip1) in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors. Clin Cancer Res 3:1943-1948, 1997. e-Pub 1997. PMID: 9815583.
- Peng D, Fan Z, Lu Y, DeBlasio T, Scher H, Mendelsohn J. Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res 56:3666-3669, 1996. e-Pub 1996. PMID: 8706005.
- Wu X, Rubin M, Fan Z, DeBlasio T, Soos T, Koff A, Mendelsohn J. Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 12:1397-403, 1996. e-Pub 1996. PMID: 8622855.
- Wu X, Fan Z, Masui H, Rosen N, Mendelsohn J. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 95:1897-1905, 1995. e-Pub 1995. PMID: 7706497.
- Fan Z, Lu Y, Wu X, DeBlasio A, Koff A, Mendelsohn J. Prolonged induction of p21Cip1/WAF1/CDK2/PCNA complex by epidermal growth factor receptor activation mediates ligand-induced A431 cell growth inhibition. J Cell Biol 131:235-242, 1995. e-Pub 1995. PMID: 7559780.
- Tang ZY, Yu YQ, Zhou XD, Ma ZC, Yang BH, Lin ZY, Lu JZ, Liu KD, Fan Z, Zeng ZC. Treatment of unresectable primary liver cancer: with reference to cytoreduction and sequential resection. World J Surg 19:47-52, 1995. e-Pub 1995. PMID: 7740810.
- Fan Z, Lu Y, Wu X, Mendelsohn J. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 269:27595-27602, 1994. e-Pub 1994. PMID: 7961676.
- Tang Z, Yu Y, Zhou X, Ma Z, Liu K, Lu J, Lin Z, Zeng Z, Fan Z, Yang B, Xie H. The role of targeting therapy in cytoreduction and sequential resection of unresectable hepatocellular carcinoma. Chin J Cancer Res 6:24-30, 1994. e-Pub 1994.
- Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well-established A431 cell xenografts. Cancer Res 53:4637-4642, 1993. e-Pub 1993. PMID: 8402640.
- Fan Z, Mendelsohn J, Masui H, Kumar R. Regulation of epidermal growth factor receptor in NIH3T3/HER14 cells by antireceptor monoclonal antibodies. J Biol Chem 268:21073-21079, 1993. e-Pub 1993. PMID: 8407944.
- Fan Z, Masui H, Altas I, Mendelsohn J. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 53:4322-4328, 1993. e-Pub 1993. PMID: 8364927.
- Tang Z, Liu K, Fan Z, Lu J, Zhang Y, Bao Y, Zeng Z, Zhou D, Tang W, Xia X, Yang R, Li J, Wei C, Wu B, Lin Z, Ma Z, Zhou X, Yu Y, Yang B, Zhao H, Xie H, Schroder CH, Arosio P. A decade's studies on the immunotargeting therapy of hepatocellular carcinoma. Antibody Immunoconj Radiophar 6:155-165, 1993. e-Pub 1993.
- Liu K, Tang Z, Lu J, Fan Z, Yu Y. [Evaluation of radioimmunotherapy in the multimodality treatment of hepatocellular carcinoma (HCC)]. Zhonghua Zhong Liu Za Zhi 14:430-2, 1992. e-Pub 1992. PMID: 1338985.
- Fan Z, Tang Z, Liu K, Zhou D, Lu J, Yuan A, Zhao H. Radioiodinated anti-hepatocellular carcinoma (HCC) ferritin. Targeting therapy, tumor imaging and anti-antibody response in HCC patients with hepatic arterial infusion. J Cancer Res Clin Oncol 118:371-376, 1992. e-Pub 1992. PMID: 1316355.
- Tang Z, Liu K, Fan Z, Lu J, Hou Z, Zhao H, Chen S, Yuan A, Zhou Y, Yang K, Wu Y. Tumor imaging and target therapy for hepatocellular carcinoma. China Cancer 1:24-26, 1992. e-Pub 1992.
- Tang ZY, Yu YQ, Zhou XD, Ma ZC, Lu JZ, Liu KD, Lin ZY, Yang BH, Fan Z, Hou Z. Cytoreduction and sequential resection: a hope for unresectable primary liver cancer. J Surg Oncol 47:27-31, 1991. e-Pub 1991. PMID: 2023418.
- Fan Z, Yuan A, Tang Z, Zhao H. Radioimmunoimaging of hepatocellular carcinoma using anti-ferritin antibodies. Chin J Digestion 11:193-195, 1991. e-Pub 1991.
- Fan Z, Tang Z, Zhou X, Arosio P. Analysis of ferritin from human hepatoma and liver by ferritin H and L subunit specific monoclonal antibodies. Tumor (Shanghai) [Chinese] 11:3-4, 1991. e-Pub 1991.
- Tang Z, Yu Y, Zhou X, Ma Z, Lu J, Liu K, Lin Z, Yang B, Fan Z, Hou Z, Zhang M. Cytoreduction and sequential resection for unresectable hepatocellular carcinoma. Tumor (Shanghai) [Chinese] 11:145-147, 1991. e-Pub 1991.
- Tang ZY, Liu KD, Bao YM, Lu JZ, Yu YQ, Ma ZC, Zhou XD, Yang R, Gan YH, Lin ZY, Fan Z, Hou Z. Radioimmunotherapy in the multimodality treatment of hepatocellular carcinoma with reference to second-look resection. Cancer 65:211-5, 1990. e-Pub 1990. PMID: 1688507.
- Zhou D, Tang Z, Fan Z. Detection of anti-antibody in the sera of patients with hepatocellular carcinoma following radioimmunotherapy. Acta Academiae Medicinae Shanghai [Chinese] 17:451-453, 1990. e-Pub 1990.
- Fan Z, Tang Z, Liu K, Yi Q, Zhang Z. Factors influencing the effects of radioimmunotherapy of liver cancer. Acta Academiae Medicinae Shanghai [Chinese] 17:426-430, 1990. e-Pub 1990.
- Fan Z, Tang Z, Yuan A, Zhao H. Radioimmunoimaging of primary liver cancer in patients with radioiodinated anti-human hepatocellular carcinoma isoferritin antibody. Acta Academiae Medicinae Shanghai [Chinese] 17:405-408, 1990. e-Pub 1990.
- Tang Z, Liu K, Fan Z, Lu J, Zhang Y, Hou Z, Bao Y, Zhou D, Tang W, Xia X, Yang Y, Yu Z, Lin Z, Ma Z, Zhou X, Yu Y, Yang B, Zhao H, Yuan A, Zhou Y. Radioimmunotherapy of hepatocellular carcinoma: experimental and clinical studies. Tumor (Shanghai) [Chinese] 10:241-244, 1990. e-Pub 1990.
- Fan Z, Zhou X, Gu H, Zhang R, Wang Y. Anti-lactate dehydrogenase-C4 (LDH-C4) antibody-induced immuno-contraception in female rats. Acta Academiae Medicinae Shanghai [Chinese] 17:81-84, 1990. e-Pub 1990.
- Fan Z, Zhou X, Gu H, Zhang R, Wang Y. Immunohistochemical localization of lactate-dehydrogenase-C4 (LDH-C4) in the different stages of rat sperm. Acta Academiae Medicinae Shanghai [Chinese] 16:423-426, 1989. e-Pub 1989.
- Fan Z, Zhou X, Zhang R, Gu H, Wang Y. Purification and immunospecificity analysis of rat sperm lactate dehydrogenase-C4 (LDH-C4). Acta Academiae Medicinae Shanghai [Chinese] 16:253-258, 1989. e-Pub 1989.
Invited Articles
- Andratschke NH, Dittmann KH, Mason KA, Fan Z, Liao Z, Komaki R, Ang KK, Milas L. Epidermal growth factor receptor as a target to improve treatment of lung cancer. Clin Lung Cancer 5:340-52, 2004. e-Pub 2004. PMID: 15217533.
- Milas L, Fan Z, Andratschke NH, Ang KK. Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. (Monograph). Int J Radiat Oncol Biol Phys 58:966-71, 2004. e-Pub 2004. PMID: 14967457.
- Fan Z, Mendelsohn J. Therapeutic application of anti-growth factor receptor antibodies. (Review). Curr Opin Oncol 10:67-73, 1998. e-Pub 1998. PMID: 9466487.
- Fan Z. Sperm-specific lactate dehydrogenase isoenzyme LDH-C4 and immuno-contraception. [Chinese] (Review). Current Overseas Medicine 6:78-82, 1989. e-Pub 1989.
Editorials
- Mendelsohn J, Fan Z. Epidermal growth factor receptor family and chemosensitization. J Natl Cancer Inst 89(5):341-3, 1997. PMID: 9060954.
Abstracts
- Fan Z. Akt as a target for enhancing breast cancer chemotherapy and radiotherapy. EORTC-NCI-AACR: Molecular Targets and Cancer Therapeutics (Frankfurt, Germany, 11/19-22/2002), 2002. e-Pub 2002.
- Lu Y, Knuefermann C, Liang K, Jin W, Fan Z. Role of the phosphatidylinositol-kinase pathway in mediating resistance of breast cancer cells to chemotherapy and radiotherapy. The Future of Breast Cancer: An International Breast Cancer Congress, Paradise Island, Bahamas, 7/31-8/3/02, 2002. e-Pub 2002.
Book Chapters
- Milas L, Fan Z, Mason KA, Ang KK. Role of epidermal growth factor receptor (EGFR) and its inhibition in radiotherapy. In: Modification of Radiation Response. Springer-Verlag, 189-204, 2003.
- Mendelsohn J, Baird A, Fan Z, Markowitz S. Growth factors and their receptors in epithelial malignancies. In: Molecular Basis of Cancer. 2nd edition. WB Saunders, 137-161, 2001.
- Fan Z, Mendelsohn J. Breast cancer therapy with antibodies to EGF receptor and HER-2/neu. In: Contemporary Cancer Research Series: Breast Cancer. Humana Press, 419-436, 1999.
- Mendelsohn J, Baselga J, Wu X, Peng D, Brown C, Chou JL, Masui H, Fan Z. EGF receptor inhibition by antibody as anticancer therapy. In: EGF receptor in tumor growth and progression. Ernst Schering Research Foundation Workshop 19, Springer-Verlag, 234-251, 1997.
- Mendelsohn J, Fan Z, Baselga J. Combination therapy with cisplatinum and EGF receptor blockade. In: Platinum and other metal coordination compounds in cancer chemotherapy-2. Plenum Press, 155-163, 1996.
- Tang Z, Yu Y, Zhou X, Ma Z, Yang B, Lin Z, Lu J, Liu K, Fan Z, Zeng Z. B1.An analysis of 55 patients with cytoreduction and sequential resection for surgically verified unresectable hepatocellular carcinoma. In: Progress on catheterization and stage-resection in hepatoma. Jiangxi Science & Technology Publishing House, 140-148, [Chinese], 1994.
Selected Presentations & Talks
Local Presentations
- 2020. Novel bispecific targeting - Dialogue with ORBIT update. Conference. Novel bispecific targeting - Dialogue with ORBIT update. Houston, TX, US.
- 2020. Novel bispecific targeting - Dialogue with ORBIT. Conference. Novel bispecific targeting - Dialogue with ORBIT. Houston, TX, US.
- 2012. New Platforms for Next Generation of Therapeutic Antibodies - Development of "designed" therapeutic antibodies. Conference. New Platforms for Next Generation of Therapeutic Antibodies - Development of "designed" therapeutic antibodies. Houston, TX, US.
- 2011. Novel Anthrapyrazolone Derivatives for Cancer Therapy. Conference. Novel Anthrapyrazolone Derivatives for Cancer Therapy. Houston, TX, US.
- 2008. Developing EGFR Co-targeting Strategies: Rationale and Approaches. Conference. Developing EGFR Co-targeting Strategies: Rationale and Approaches. Houston, TX, US.
- 2006. Brk as a Co-target for Enhancing EGFR-targeted Therapy for Breast Cancer. Conference. Brk as a Co-target for Enhancing EGFR-targeted Therapy for Breast Cancer. Houston, TX, US.
- 2003. Targeting EGFR for Triple Negative Breast Cancer. Conference. Targeting EGFR for Triple Negative Breast Cancer. Houston, TX, US.
- 2002. EGFR-targeted Therapy - Promise and Challenges. Conference. EGFR-targeted Therapy - Promise and Challenges. Houston, TX, US.
- 2002. Targeting EGFR-mediated Cell Signaling for Cancer Therapy. Conference. Targeting EGFR-mediated Cell Signaling for Cancer Therapy. Houston, TX, US.
- 1999. Targeting EGFR for Radiosensitization. Conference. Targeting EGFR for Radiosensitization. Houston, TX, US.
- 1999. Role of EGFR in Prostate Cancer. Conference. Role of EGFR in Prostate Cancer. Houston, TX, US.
- 1998. EGFR-mediated Cell Signaling in Cancer. Conference. EGFR-mediated Cell Signaling in Cancer. Houston, TX, US.
- 1998. Regulation of Cell Cycle by EGF Receptors. Conference. Regulation of Cell Cycle by EGF Receptors. Houston, TX, US.
- 1998. Anti-EGFR Therapeutic Antibodies. Conference. Anti-EGFR Therapeutic Antibodies. Houston, TX, US.
- 1997. Regulation of Cell Cycle and Cell Death by EGF Receptors. Conference. Regulation of Cell Cycle and Cell Death by EGF Receptors. Houston, TX, US.
- 1997. Role of EGFR as a Cell Survival Signaling. Conference. Role of EGFR as a Cell Survival Signaling. Houston, TX, US.
- 1996. Role of EGFR in Ovarian Cancer. Conference. Role of EGFR in Ovarian Cancer. Houston, TX, US.
- 1996. Role of EGFR in Cell Cycle Regulation. Conference. Role of EGFR in Cell Cycle Regulation. Houston, TX, US.
National Presentations
- 2023. San Antonio Annual Breast Cancer Symposium 2023. Conference. San Antonio Breast Cancer Symposium. San Antonio, TX, US.
- 2023. SITC 2023 Annual Meeting. Conference. SITC 2023 Annual Meeting. San Diego, CA, US.
- 2023. ISEV 2023 ANNUAL MEETING 2023. Conference. ISEV 2023 ANNUAL MEETING 2023. Seatlle, WA, US.
- 2023. AACR 2023 Annual Meeting. Conference. AACR 2023 Annual Meeting. Orlando, FL, US.
- 2022. SITC's 37th Annual Meeting & Pre-Conference Programs. Conference. SITC's 37th Annual Meeting & Pre-Conference Programs. Boston, MA, US.
- 2022. AACR Annual Meeting 2022. Conference. AACR Annual Meeting 2022. New Orleans, LA, US.
- 2021. AACR Virtual Annual Meeting 2021. Conference. AACR Virtual Annual Meeting 2021, US.
- 2019. Tumor Immunology and Immunotherapy. Conference. AACR Tumor Immunology and Immunotherapy. Boston, MA, US.
- 2007. Requirement of downregulation of hypoxia-inducible factor-1 alpha for antitumor activity of epidermal growth factor receptor-targeted cancer therapy (Li X, Lu Y, Liang K, Pan T, & Fan Z.). Conference. 98th AACR Annual Meeting - MiniSymposium presentation. Los Angeles, CA, US.
- 2006. Akt kinase activity is regulated by autophosphorylation at threonine-72 and serine-246 residues (Li X., Lu Y., Jin W., Liang W., Mills. GB, & Fan Z.). Conference. 97th AACR Annual Meeting - MiniSymposium presentation. Washington, DC, US.
- 2002. Targeting PI3K/AKT for enhancing breast cancer chemotherapy and radiotherapy. Conference. Era of Hope: The Department of Defense Breast Cancer Research Program Meeting - Platform Presentation. Orlando, FL, US.
- 2000. Cell Cycle Arrest and Apoptosis induced by anti-EGF receptor monoclonal antibody. Conference. 8th Annual Radiation Workshop at Round Top: Biology based combined modality radiotherapy. Roundtop, TX, US.
International Presentations
- 2006. Hypoxia inducible factor-1 as a rationalized co-target for epidermal growth factor receptor-targeted cancer therapy. Conference. 4th Annual Congress of International Drug Discovery Science and Technology. Dalian, CN.
- 2004. Targeting the epidermal growth factor receptor for cancer therapy. Conference. 2004 Symposium of National Education/New Technology Application on Cancer Biotherapy. Fuzhou, CN.
- 2003. Akt as a target for chemo- and radiosensitization. Conference. Oral Presentation, 8th World Congress on Advances in Oncology/6th International Symposium on Molecular Medicine. Hersonissos, GR.
Formal Peers
- 2017. Incorporating cancer immunotherapy and targeted cancer therapies. Invited. Incorporating cancer immunotherapy and targeted cancer therapies. Xi'an, CN.
- 2012. Development of Novel Small Molecule Anti-Cancer Compounds Targeting the Akt/mTOR/HIF-1α Pathway. Invited. Development of Novel Small Molecule Anti-Cancer Compounds Targeting the Akt/mTOR/HIF-1α Pathway. Lost Pines, TX, US.
- 2012. Targeted Cancer Therapy - Rationale and Approaches. Invited. Targeted Cancer Therapy - Rationale and Approaches. Wuhan, CN.
- 2012. Strategies to Overcoming Resistance to EGFR-targeted Therapy. Invited. Strategies to Overcoming Resistance to EGFR-targeted Therapy. Shanghai, CN.
- 2012. Targeting EGFR for Cancer Therapy - Updates. Invited. Targeting EGFR for Cancer Therapy - Updates. Shanghai, CN.
- 2011. Role of Inhibiting HIF in EGFR-targeted Cancer Therapy. Invited. Role of Inhibiting HIF in EGFR-targeted Cancer Therapy. Houston, TX, US.
- 2009. Understanding the Role of Brk in Breast Cancer. Invited. Understanding the Role of Brk in Breast Cancer. Galveston, TX, US.
- 2008. Developing EGFR Co-targeting Strategies: Rationale and Approaches. Invited. Developing EGFR Co-targeting Strategies: Rationale and Approaches. Yixing, CN.
- 2008. Developing EGFR Co-targeting Strategies: Rationale and Approaches. Invited. Developing EGFR Co-targeting Strategies: Rationale and Approaches. Changzhou, CN.
- 2008. Developing EGFR Co-targeting Strategies: Rationale and Approaches. Invited. Developing EGFR Co-targeting Strategies: Rationale and Approaches. Hangzhou, CN.
- 2008. Developing EGFR Co-targeting Strategies: Rationale and Approaches. Invited. Developing EGFR Co-targeting Strategies: Rationale and Approaches. Wuhan, CN.
- 2008. Developing EGFR Co-targeting Strategies: Rationale and Approaches. Invited. Developing EGFR Co-targeting Strategies: Rationale and Approaches. Xi'an, CN.
- 2008. Developing EGFR Co-targeting Strategies: Rationale and Approaches. Invited. Developing EGFR Co-targeting Strategies: Rationale and Approaches. Shanghai, CN.
- 2008. Developing EGFR Co-targeting Strategies: Rationale and Approaches. Invited. Developing EGFR Co-targeting Strategies: Rationale and Approaches. Shanghai, CN.
- 2008. Developing EGFR Co-targeting Strategies: Rationale and Approaches. Invited. Developing EGFR Co-targeting Strategies: Rationale and Approaches. Aurora, CO, US.
- 2008. Updates on targeting EGFR for cancer therapy. Visiting. Updates on targeting EGFR for cancer therapy. Shanghai, CN.
- 2008. Updates on targeting EGFR for cancer therapy. Visiting. Updates on targeting EGFR for cancer therapy. Xi'an, CN.
- 2007. Improving HER/ErbB-targeted Therapeutics. Invited. Improving HER/ErbB-targeted Therapeutics. Shanghai, CN.
- 2007. Improving HER/ErbB-targeted Therapeutics. Invited. Improving HER/ErbB-targeted Therapeutics. Xi'an, CN.
- 2007. Targeting EGFR for cancer therapy. Visiting. Targeting EGFR for cancer therapy. Xi'an, CN.
- 2006. Tumor Resistance to HER/ErbB-targeted Therapeutics. Invited. Tumor Resistance to HER/ErbB-targeted Therapeutics. Xi'an, CN.
- 2002. Sensitivity of and Resistance to EGF receptor-targeted cancer therapy - Laboratory studies. Invited. Sensitivity of and Resistance to EGF receptor-targeted cancer therapy - Laboratory studies. Konstanz, DE.
- 2002. EGFR as a Target for Cancer Therapy: Promise and Challenge. Invited. EGFR as a Target for Cancer Therapy: Promise and Challenge. Buffalo, NY, US.
Grant & Contract Support
| Date: | 2021 - 2026 |
| Title: | Developing novel bispecific antibodies for cancer treatment |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1-R01-CA262288-01 |
| Date: | 2020 - 2025 |
| Title: | Targeting metabolic vulnerability in angiogenesis-inhibited HER2-overexpressing breast cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Date: | 2020 - 2022 |
| Title: | Enhancing trastuzumab response via improving tumor-infiltrating T cell metabolism |
| Funding Source: | Emerson Collective |
| Role: | PI |
| Date: | 2020 - 2024 |
| Title: | Development of a novel strategy for tumor delivery of MHC-I-compatible peptides for cancer immunotherapy |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP200271 |
| Date: | 2019 - 2024 |
| Title: | Temporospatial co-targeting of HER2 and VEGFA for breast cancer therapy |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01CA243461 |
| Date: | 2019 - 2022 |
| Title: | Combating inflammatory breast cancer with a novel targeted therapy |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | PI |
| ID: | BC190749 |
| Date: | 2019 - 2024 |
| Title: | Temporospatial co-targeting HER2 and VEGFA for breast cancer therapy |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | GRANT12760106/R01 CACA243461-01 |
| Date: | 2019 - 2024 |
| Title: | Developing an effective cetuximab-based targeted therapy for triple-negative breast cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | GRANT12697158/ 1 R01 CA239674-01 |
| Date: | 2018 - 2023 |
| Title: | A novel strategy for combating tumor progression and metastasis of HER2-overexpressing breast cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1-R01-CA232306-01A1 |
| Date: | 2018 - 2023 |
| Title: | Harnessing noncancer immunity for cancer immunotherapy |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1-R01-CA232726-01 |
| Date: | 2018 - 2023 |
| Title: | A novel strategy for combating tumor progression and metastasis of HER2-overexpressing breast cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1-R01-CA232306-01 |
| Date: | 2017 - 2022 |
| Title: | Temporospatial co-targeting intervention as a mechanism of breast cancer therapeutics |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1-R01-CA228163-01 |
| Date: | 2015 - 2016 |
| Title: | Evaluation of Brk Inhibitor in Breast Cancer |
| Funding Source: | ONO Pharmaceuticals |
| Role: | PI |
| ID: | NA |
| Date: | 2014 - 2019 |
| Title: | A novel approach for improving anti-VEGF therapy for breast cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Date: | 2014 - 2017 |
| Title: | Improving response to HER2-targeted therapy for breast cancer via enhancing antiangiogenic activity |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| Date: | 2014 - 2022 |
| Title: | A novel targeted therapy for HNSCC based on a novel activity of cetuximab |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 5-R01-CA179015-05 |
| Date: | 2014 - 2017 |
| Title: | Rerouting preexisting host vaccine T-cell immunity towards breast cancer cells |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | PI |
| ID: | BC132021 |
| Date: | 2013 - 2018 |
| Title: | Metabolic effects of targeted cancer therapy |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1-R01-CA166466 |
| Date: | 2011 - 2015 |
| Title: | Developing a novel recombinant antibody for treatment of oral cancer |
| Funding Source: | NIH/NIDCR |
| Role: | PI |
| ID: | 1-R21-DE021883 |
| Date: | 2011 - 2016 |
| Title: | EGFR-Targeted Multimodal Therapy of Refractory HNSCC |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1-R01-CA158449 |
| Date: | 2011 - 2014 |
| Title: | A novel role of EMMPRIN in activation of cancer-associated fibroblasts in breast cancer |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | PI |
| ID: | W81-XWH-11-1-0107 -Idea award |
| Date: | 2011 - 2013 |
| Title: | Targeting transformation of fibroblasts to cancer-associated fibroblasts for cancer therapy |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| Date: | 2010 - 2011 |
| Title: | MMP14-mediated EMMPRIN Ectodomain Shedding As a Novel Mechanism of Breast Cancer Cell Migration |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | PI |
| ID: | BC097639 |
| Date: | 2010 - 2011 |
| Title: | Validating EMMPRIN Upregulation as A Novel Mechanism of Acquired Resistance to Anti-HER2 Therapy in Breast Cancer |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | PI |
| ID: | BC097587 |
| Date: | 2010 - 2012 |
| Title: | Developing Brk and HER family co-targeting therapies for breast cancer |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | PI |
| ID: | BC097933 |
| Date: | 2010 - 2015 |
| Title: | Validating Brk as a novel target for breast cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1-R01-CA149596-01A1 |
| Date: | 2010 - 2013 |
| Title: | Development of a novel anti-EGFR antibody-protamine recombinant protein for in vivo delivery of small interfering RNAs for cancer therapy |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | HIRP100708 |
| Date: | 2010 - 2015 |
| Title: | Development of Brk Inhibitors |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1-R01-CA149596-01 |
| Date: | 2010 - 2014 |
| Title: | Understanding the role of autophagy in EGFR-targeted therapy |
| Funding Source: | Cancer Prevention Research Institute of Texas |
| Role: | PI |
| Date: | 2010 - 2012 |
| Title: | Targeting transformation of fibroblasts to cancer-associated fibroblasts for breast cancer therapy |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | PI |
| ID: | W81XWH-09-BCRP-IDEA |
| Date: | 2009 - 2011 |
| Title: | Mechanisms of tumor resistance to anti-HER/ErbB therapeutics |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 3-R01-CA1239036-02S1 |
| Date: | 2009 - 2011 |
| Title: | Mechanisms of tumor resistance to anti-HER/ErbB therapeutics |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Date: | 2009 - 2014 |
| Title: | HIF-1α, a complementary target for EGFR-targeted therapy |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1-R01-CA133232-01 |
| Date: | 2009 - 2010 |
| Title: | A novel role of MT1-MMP-mediated CD147 ectodomain shedding and CD147 interaction with the cytoskeleton protein actin in breast cancer cell migration |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | PI |
| ID: | W81XWH-08-BCRP-CA |
| Date: | 2009 - 2012 |
| Title: | Elucidation of a novel pathway through which Brk degrades p53 via ubiquitination and confers cellular resistance to p53-dependent induction of apoptosis |
| Funding Source: | Susan G. Komen Breast Cancer Foundation |
| Role: | PI |
| ID: | KG091442 |
| Date: | 2008 - 2010 |
| Title: | Development of novel small molecule anti-cancer compounds targeting the Akt/mTOR/HIF-1α pathway |
| Funding Source: | CTT/TI-3D |
| Role: | PI |
| Date: | 2008 - 2015 |
| Title: | Mechanisms of tumor resistance to anti-HER/ErbB therapeutics |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1-R01-CA129036 |
| Date: | 2007 - 2008 |
| Title: | Unraveling a novel role of Brk in regulating EGFR in triple-negative breast cancer |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | PI |
| ID: | W81XWH-07-1-0526 |
| Date: | 2007 - 2013 |
| Title: | Checkpoint response and platinum drug sensitivity |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 1-R01-CA127263 |
| Date: | 2006 - 2010 |
| Title: | Breast tumor kinase as a complementary target for sensitizing breast cancer to epidermal growth factor receptor-targeted therapy |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | PI |
| ID: | W81XWH-06-1-0544 |
| Date: | 2003 - 2005 |
| Title: | PDK1, a preferred therapeutic target for the PI-3 kinase pathway in human breast cancer |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | PI |
| ID: | DAMD 17-03-1-0617 |
| Date: | 2002 - 2003 |
| Title: | Targeting PI-3K/Akt pathway for the enhancement of gemcitabine-induced cytotoxicity in human breast cancer cells |
| Funding Source: | Eli Lilly & Company, Indianapolis |
| Role: | PI |
| Date: | 2001 - 2024 |
| Title: | Exploration of novel potential therapies for breast cancer |
| Funding Source: | Breast Cancer Research Foundation |
| Role: | PI |
| ID: | BCRF-23-051 |
| Date: | 2000 - 2001 |
| Title: | Exploration of novel potential therapies for breast cancer |
| Funding Source: | Breast Cancer Research Foundation |
| Role: | Co-I |
| Date: | 2000 - 2004 |
| Title: | Role of PKB/Akt pathway in breast cancer chemotherapy |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | PI |
| ID: | DAMD 17-00-1-0461 |
| Date: | 2000 - 2002 |
| Title: | Anti-angiogenic therapy of human prostate cancer |
| Funding Source: | ImClone System, Inc |
| Role: | PI |
| Date: | 1999 - 2000 |
| Title: | Exploration of novel potential therapies for breast cancer |
| Funding Source: | The Breast Cancer Research Foundation |
| Role: | Co-I |
| Date: | 1999 - 2003 |
| Title: | Genes differentially activated by Akt1 and Akt2 in human ovarian cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 5P50 CA83639 PC-CD and PC-DRP |
| Date: | 1995 - 2000 |
| Title: | Regulation of chemotherapy sensitivity by signal transduction pathways |
| Funding Source: | NIH/NCI, SPORE in Breast Cancer, Program 3 |
| Role: | Co-I |
| ID: | P50CA68425 |
| Date: | 1995 - 1999 |
| Title: | Antireceptor Monoclonal antibody in cancer treatment |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | U19CA37641 |
| Date: | 1994 - 1999 |
| Title: | Antitumor activities of antireceptor antibodies |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R37CA42060 |
Patient Reviews
CV information above last modified March 27, 2025